3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
2
Phase 2/3
1
Status
Unknown
2
Recruiting
2
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Polycystic Ovary Syndrome
2
Hyperandrogenism
2
Interventions
Magnetic Resonance Spectroscopy
17
Cyclophosphamide
16
fludarabine
12
Specimen Handling
12
Fluorodeoxyglucose F18
7
pembrolizumab
6
X-Rays
6
Nivolumab
6
Temozolomide
5
Radiotherapy
5
Immunotherapy, Adoptive
5
lenvatinib
4
Paclitaxel
4
Leukapheresis
4
Immune Checkpoint Inhibitors
4
Etoposide
4
Cisplatin
4
Carboplatin
4
ruxolitinib
3
fluciclovine F-18
3
Tirzepatide
3
Surgical Procedures, Operative
3
Doxorubicin
3
Dasatinib
3
Cholecalciferol
3
Biopsy
3
68Ga-FAPI
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
tislelizumab
2
palbociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Recruiting
×
Progesterone
×
Clear all
NCT00929006
2025-08-05
CRM003
University of Virginia
Phase EARLY_PHASE1
Recruiting
36 enrolled
NCT03068910
2025-08-05
CRM008
University of Virginia
Phase EARLY_PHASE1
Recruiting
32 enrolled